Cyclooxygenase-2 inhibitor SC-236 [4-[5-(4-chlorophenyl)-3- (trifluoromethyl)-1-pyrazol-1-l] benzenesulfonamide] suppresses nuclear factor-κB activation and phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and c-Jun N-terminal kinase in human mast cell line cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 1, 2005, Pages 27-34

  Kim, Su Jin ^a,b   Jeong, Hyun Ja ^a,c   Choi, In Young ^a,c   Lee, Kang Min ^b   Park, Rae Kil ^c   Hong, Seung Heon ^c   Kim, Hyung Min ^a  

^a Kyung Hee University   (South Korea)

^b Chonbuk National University   (South Korea)

^c Wonkwang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CALCIMYCIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; INTERLEUKIN 8; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PHORBOL 13 ACETATE 12 MYRISTATE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME REPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MAST CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CALCIMYCIN; CELL LINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOKINES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, REPORTER; HUMANS; IMMUNOHISTOCHEMISTRY; IONOPHORES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUCIFERASES; MAST CELLS; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-TYROSINE-PHOSPHATASE; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; STIMULATION, CHEMICAL; SULFONAMIDES; TETRADECANOYLPHORBOL ACETATE; TETRAZOLIUM SALTS; THIAZOLES;

EID: 23044460984     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.082792     Document Type: Article

References (40)

1. Abdel-Majid RM and Marshall JS (2004) Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J Immunol 172:1227-1236.
2. Adwanikar H, Karim F, and Gereau RW 4th (2004) Inflammation persistently enhances nocifensive behaviors mediated by spinal group I mGluRs through sustained ERK activation. Pain 111:125-135.
3. Barnes PJ and Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. New Engl J Med 336:1066-1071.
4. 2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. Thorax 59:459-464.
5. Bokemeyer D, Lindemann M, and Kramer HJ (1998) Regulation of mitogen-activated protein kinase phosphatase-1 in vascular smooth muscle cells. Hypertension 32:661-667.
6. Borsch-Haubold AG, Pasquet S, and Watson SP (1998) Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. J Biol Chem 273:28766-28772.
7. Castano E, Bartrons R, and Gil J (2000) Inhibition of cyclooxygenase-2 decreases DNA synthesis induced by platelet-derived growth factor in Swiss 3T3 fibroblasts. J Pharmacol Exp Ther 293:509-513.
8. Chen P, Li J, Barnes J, Kokkonen GC, Lee JC, and Liu Y (2002) Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol 169:6408-6416.
9. Cobb MH and Goldsmith EJ (2000) Dimerization in MAP-kinase signaling. Trends Biochem Sci 25:7-9.
10. Cramer T, Yamanishi Y, and Clausen BE (2003) HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112:645-657.
11. Everts B, Wahrborg P, and Hedner T (2000) COX-2-specific inhibitors: the emergence of a new class of analgesic and anti-inflammatory drugs. Clin Rheumatol 19:331-340.
12. Gordon JR, Burd PR, and Galli SJ (1990) Mast cells as a source of multifunctional cytokines. Immunol Today 11:458-464.
13. Guo X, Gerl RE, and Schrader JW (2003) Defining the involvement of p38alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase. J Biol Chem 278:22237-22242.
14. Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D, Koki A, and Tripp CS (2002) Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 46:1789-1803.
15. Hollander AP, Corke KP, Freemont AJ, and Lewis CE (2001) Expression of hypoxiainducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 44:1540-1544.
16. Iijima K, Yoshikawa N, and Nakamura H (1996) Activation-induced expression of vascular permeability factor by human peripheral T cells: a non-radioisotopic semiquantitative reverse transcription-polymerase chain reaction assay. J Immunol Methods 196:199-209.
17. Jeong HJ, Na HJ, Hong SH, and Kim HM (2003) Inhibition of the stem cell factor-induced migration of mast cells by dexamethasone. Endocrinology 144:4080-4086.
18. Jung YJ, Isaacs JS, Lee S, Trepel J, and Neckers L (2003) IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17:2115-2117.
19. Kawamori T, Rao CV, Seibert K, and Reddy BS (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409-417.
20. Kim MS, Lim WK, Cha JG, An NH, Yoo SJ, Park JH, Kim HM, and Lee YM (2001) The activation of PI 3-K and PKC zeta in PMA-induced differentiation of HL-60 cells. Cancer Lett 171:79-85.
21. Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, Paik SW, and Rhee JC (2002) Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol 17:914-921.
22. Koranteng RD, Swindle EJ, Davis BJ, Dearman RJ, Kimber I, Flanagan BF, and Coleman JW (2004) Differential regulation of mast cell cytokines by both dexamethasone and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580. Clin Exp Immunol 137:81-87.
23. Lasa M, Abraham SM, Boucheron C, Saklatvala J, and Clark AR (2002) Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 22:7802-7811.
24. Lewis TS, Shapiro PS, and Ahn NG (1998) Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49-139.
25. Marone G (1998) Mast cells in rheumatic disorders: masterminded or workhorse? Clin Exp Rheumatol 16:245-249.
26. Mukaida N (2000) Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 72:391-398.
27. Murakami M, Bingham CO, Matsumoto R, Austen KF, and Arm JP (1995) IgE-dependent activation of cytokine-primed mouse cultured mast cells induces a delayed phase of prostaglandin D2 generation via prostaglandin endoperoxide synthase-2. J Immunol 155:4445-4453.
28. Oguma T, Asano K, Shiomi T, Fukunaga K, Suzuki Y, Nakamura M, Matsubara H, Sheldon HK, Haley KJ, Lilly CM, et al. (2002) Cyclooxygenase-2 expression during allergic inflammation in guinea-pig lungs. Am J Respir Crit Care Med 165:382-386.
29. Reischl IG, Coward WR, and Church MK (1999) Molecular consequences of human mast cell activation following immunoglobulin E-high-affinity immunoglobulin E receptor (IgE-FcepsilonRI) interaction. Biochem Pharmacol 58:1841-1850.
30. Risau W (1997) Mechanisms of angiogenesis Nature (Lond) 17:671-674.
31. Sakaue H, Ogawa W, Nakamura T, Mori T, Nakamura K, and Kasuga M (2004) Role of MAP kinase phosphatase-1 (MKP-1) in adipocyte differentiation. J Biol Chem 279:39951-39957.
32. Schaecher K, Goust JM, and Banik NL (2004) The effects of calpain inhibition on IkB alpha degradation after activation of PBMCs: identification of the calpain cleavage sites. Neurochem Res 29:1443-1451.
33. Schoonbroodt S, Legrand-Poels S, Best-Belpomme M, and Piette J (1997) Activation of the NF-κB transcription factor in a T-lymphocytic cell line by hypochlorous acid. Biochem J 321:777-785.
34. Stark LA, Din FVN, Zwacka RM, and Dunlop MG (2001) Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 15:1273-1275.
35. Temkin V, Kantor B, Weg V, Hartman ML, and Levi-Schaffer F (2002) Tryptase activates the mitogen-activated protein kinase/activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. J Immunol 169:2662-2669.
36. Wadgaonkar R, Pierce JW, Somnay K, Damico RL, Crow MT, Collins T, and Garcia JG (2004) Regulation of c-JUN N-terminal kinase and p38 kinase pathways in endothelial cells. Am J Respir Cell Mol Biol 1:384-400.
37. Walsh LJ, Davis MF, Xu LJ, and Savage NW (1995) Relationship between mast cell degranulation, release of TNF and inflammation in the oral cavity. J Oral Pathol Med 26:266-272.
38. Wang MJ, Jeng KC, and Kuo JS (2004) c-Jun N-terminal kinase and, to a lesser extent, p38 mitogen-activated protein kinase regulate inducible nitric oxide synthase expression in hyaluronan fragments-stimulated BV-2 microglia. J Neuroimmunol 146:50-62.
39. Wong BC, Jiang X, Fan XM, Lin MC, Jiang SH, Lam SK, and Kung HF (2003) Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 22:1189-1197.
40. Yamamoto Y, Yin MJ, Lin KM, and Gaynor RB (1999) Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274:27307-27314.